



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**



www.icar2022.it



Elenco Oral Posters

Orario	ID	Title	Presenting Author
15/06/2022 10.05 - 10.55 COVID-19: treatment strategies I			
10.05 - 10.10	116	OP 1 Real-life data on early treatment with antivirals in outpatients with mild COVID-19 symptoms	Alban Rugova, Monza
10.12 - 10.17	222	OP 2 Efficacy of licensed monoclonal antibodies and antiviral agents against the SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 and delta sub-lineage AY.4.2	Lia Fiaschi, Siena
10.19 - 10.24	229	OP 3 Sarilumab plus standard of care versus standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE Study)	Annalisa Mondì, Roma
10.26 - 10.31	241	OP 4 Safety and efficacy of antiviral agents in SARS-CoV-2 infected patients: a real-life experience	Andrea De Vito, Sassari
10.33 - 10.38	261	OP 5 Efficacy of Early Antiviral Therapies among High-Risk Patients with Mild to Moderate COVID-19	Melania Degli Antoni, Brescia
10.40 - 10.45	263	OP 6 Real life experience on the use of anti-SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression among inpatients and outpatients: a monocentric experience	Silvia Di Bari, Roma
15/06/2022 11.10 - 12.00 COVID-19: treatment strategies II			
11.10 - 11.15	89	OP 7 Use of Sotrovimab in a cohort of Pregnant Women with a high risk of COVID 19 progression: a single-center experience	Luisa Frallonardo, Bari
11.17 - 11.22	319	OP 8 Remdesivir does not influence SARS-CoV-2 RNA viral load kinetics in nasopharyngeal swab specimens of COVID-19 hospitalized patients: a real-life experience	Laura Campogiani, Roma
11.24 - 11.29	111	OP 9 Anti-spike monoclonal antibodies to prevent hospitalization in mild COVID-19: preliminary data of an ongoing large observational multicenter study (CONDIVIDIAMO)	Alessandro Soria, Monza
11.31 - 11.36	280	OP 10 Early Use of Short-Course Remdesivir and Monoclonal Antibodies May Reduce The Risk of Disease Progression in Hospitalized Patients With COVID-19: a Single Center Retrospective Study	Davide Fiore Bavaro, Bari
11.38 - 11.43	141	OP 11 Continuous Positive Airway Pressure in SARS-CoV-2 associated Acute Respiratory Distress Syndrome: timing to maximize results	Annabella Salvati, Napoli
11.45 - 11.50	284	OP 12 EpCOT: an open-label, controlled, randomized clinical trial on the efficacy of early prone-positioning in patients with mild pneumonia due to SARS-CoV-2	Miriam Fezzi, Monza
15/06/2022 11.10 - 12.00 Treatment of naive PLWH: current strategies and rapid start of ART			
11.10 - 11.15	151	OP 13 Reasons for choosing DRV/cob/FTC/TAF in ART-naïve and ART-experienced patients: data from the Icona Cohort	Daniele Tomasoni, Milano
11.17 - 11.22	35	OP 14 Blood telomere length in treatment-naïve HIV-infected adults starting dolutegravir plus lamivudine versus triple regimen with two nucleosides	Francesca Lombardi, Roma
11.24 - 11.29	297	OP 15 BIC/FTC/TAF in ART-naïve key populations: real-life data from the Icona cohort	Alessandro Tavelli, Milano
11.31 - 11.36	252	OP 16 A pilot study of the impact of a rapid ART initiation in advanced HIV disease	Roberta Gagliardini, Roma
11.38 - 11.43	281	OP 17 Rapid ART initiation in a single-center italian cohort: an observational analysis	Rachele Pincino, Sanremo
11.45 - 11.50	21	OP 18 Viro-immunological effectiveness of different integrase strand-transfer inhibitor-based antiretroviral therapy regimens. A single center retrospective study	Manuela Ceccarelli, Catania



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



Elenco Oral Posters

Orario	ID	Title	Presenting Author
15/06/2022 11.10 - 12.00 PrEP: real life experience			
11.10 - 11.15	138	OP 19 PrEP in Italy: how many people access it and what kind of services are offered?	Marco Falaguasta , Bologna
11.17 - 11.22	74	OP 20 HIV Pre-Exposure Prophylaxis (PrEP): the experience of the outpatient clinic of Perugia	Giulia Gamboni, Perugia
11.24 - 11.29	115	OP 21 Impact of a pre-exposure prophylaxis program on HIV and other sexually transmitted infections over the last three years in a third level hospital: the experience from Padua	Francesco Barbaro, Padova
11.31 - 11.36	147	OP 22 Pre-Exposure Prophylaxis (PrEP) Service in Bergamo: three-year experience	Serena Venturelli, Bergamo
11.38 - 11.43	215	OP 23 HIV Pre-exposure Prophylaxis in a Large Teaching Hospital in Milan: the CSL-PrEP Cohort experience	Angelo Roberto Raccagni, Milano
11.45 - 11.50	331	OP 24 The Italian experience of Pre-Exposure Prophylaxis (PrEP) users and serum creatinine variation: a two centers retrospective analysis	Marianna Menozzi, Modena
15/06/2022 12.15 - 13.05 Access to test and educational aspects			
12.15 - 12.20	191	OP 25 HIV testing in community-based centers and MSM premises: different settings, same needs	Alessandra Bianchi, Milano
12.22 - 12.27	306	OP 26 HIV testing: are we missing some opportunities?	Maria Mazzitelli, Padova
12.29 - 12.34	221	OP 27 Population of the Bergamo Check-Point. A first analysis of Cobatest data	Ilaria Mercurio, Bergamo
12.36 - 12.41	106	OP 28 Veneto Region "RECALL" project to discover HCV+people: the experience of the "Osservatorio Infettivologico" in Verona	Veronica Del Punta, Verona
12.43 - 12.48	218	OP 29 Prejudice and perceived HIV risk among High School Students	Caterina Pellegris, Chiuduno BG
12.50 - 12.55	260	OP 30 Pilot experience of comprehensive sexuality education among Italian adolescents: preliminary results from the EduForIST project, April 2022	Alice Chinelli, Pisa
15/06/2022 13.25 - 14.15 Predictors of COVID-19 severity			
13.25 - 13.30	29	OP 31 Hospitalization for COVID-19 or with SARS-CoV-2 infection during two different epidemic periods in Milan, Italy: data from Luigi Sacco Hospital registry	Andrea Giacomelli, Milano
13.32 - 13.37	104	OP 32 Prognostic value of transaminases and bilirubin levels at admission to hospital on disease progression and mortality in patients with COVID-19 - an observational retrospective study	Roberta Palladino, Napoli
13.39 - 13.44	80	OP 33 Early predictors of clinical deterioration in a cohort of outpatients with COVID-19 in Southern Italy: a multicenter observational study	Caterina Monari, Napoli
13.46 - 13.51	317	OP 34 Risk factors for in-hospital mortality in COVID-19 patients with end stage renal diseases requiring maintenance hemodialysis	Marta Chiuchiarelli, Roma
13.53 - 13.58	132	OP 35 Clinical characteristics and outcomes of COVID-19 hospitalized patients in the current pandemic phase	Edoardo Paolo Drago, Foggia
14.00 - 14.05	275	OP 36 Laboratory and clinical biomarkers helps to predict severity of CT score in COVID19 patients: an observational study	Ilaria de Luca, Caserta



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



Elenco Oral Posters

Orario	ID	Title	Presenting Author
15/06/2022 13.25 - 14.15 HCV eradication: general and key populations			
13.25 - 13.30	140	OP 37 Long-term outcomes in GT3 HCV/HIV co-infected subjects treated with DAAs: impact on metabolic profile	Alessia Siribelli, Milano
13.32 - 13.37	148	OP 38 Chronic Hepatitis C cascade of care in Prisoners. Is there still some work to be done? Analysis of two penitentiaries in northern Italy	Anna Cambianica, Brescia
13.39 - 13.44	129	OP 39 HCV point of care screening in people tested for SARS-CoV-2 in a social-housing neighbourhood of Milan, Italy	Martina Beltrami, Milano
13.46 - 13.51	200	OP 40 Hepatitis C virus (HCV) micro-elimination in the hospital setting: the results of the HCV Caserta hospital project	Mariantonietta Pisaturo, Napoli
13.53 - 13.58	32	OP 41 Patients' reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care and treatment	Luca Ceccarelli, Pisa
14.00 - 14.05	183	OP 42 Characterisation of viral infections in a cohort of migrants living in southern Italy	Salvatore Capuano, Caserta
15/06/2022 14.30 - 15.20 Viro-immunological correlates of COVID-19 severity			
14.30 - 14.35	58	OP 43 PTX3 is a strong predictor of death among patients with COVID-19	Giuseppe Lapadula, Monza
14.37 - 14.42	150	OP 44 The role of antigen load on viral clearance and severity in SARS-CoV-2 infection	Tommaso Clemente, Milano
14.44 - 14.49	307	OP 45 Dysregulation in IFN-omega levels and anti-IFN-omega neutralizing antibodies correlate with biochemical and hematological parameters predictive of disease severity in COVID-19 male patients	Federica Frasca, Roma
14.51 - 14.56	92	OP 46 Characterization of IFN response in PBMC from children and adolescent after SARS-CoV-2 infection	Leonardo Sorrentino, Roma
14.58 - 15.03	274	OP 47 Immunological profiles of SARS-CoV-2 infection: the link between cytokine storm, clinical severity and post-COVID syndrome	Alberico Parente, Roma
15.05 - 15.10	206	OP 48 Respiratory and peripheral IFN response and frequency of T cell activation in COVID-19 patients	Letizia Santinelli, Roma
15/06/2022 14.30 - 15.20 Issues on mental health, sexual health and STIs			
14.30 - 14.35	166	OP 49 Predictors of mental and sexual health after COVID-19 Pandemic in a group of MSM living with HIV	Filippo Maria Nimbi, Roma
14.37 - 14.42	295	OP 50 Single nucleotide polymorphisms affecting neuroinflammation biomarkers in different clinical groups of HIV-affected patients	Jessica Cusato, Torino
14.44 - 14.49	63	OP 51 Treatment response in syphilis reinfection among People living with HIV: high baseline titer and delayed assessment affects the risk of serological-non-response	Giorgio Tiecco, Brescia
14.51 - 14.56	23	OP 52 Increasing incidence of Mycoplasma genitalium infection in PLWHIV and PrEP users	Roberto Rossotti, Milano
14.58 - 15.03	168	OP 53 Alteration of IFN pathways in anal cells from HIV-1/HPV co-infected men	Matteo Fracella, Roma
15.05 - 15.10	338	OP 54 Efficacy of late HPV vaccination in young HIV+ MSM	Eugenio Nelson Cavallari, Roma



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



Elenco Oral Posters

Orario	ID	Title	Presenting Author
15/06/2022 15.35 - 16.25 Neuropsychological complications in COVID-19			
15.35 - 15.40	302	OP 55 Dementia and COVID-19 outcomes: findings from a multicentric study in Campania region	Roberta Astorri, Napoli
15.42 - 15.47	290	OP 56 COVID-19 neurocognitive impairment (COVID-19-NCI): an attempt for definition and clinical assessment	Giulia Del Duca, Roma
15.49 - 15.54	285	OP 57 Neuropsychological performance (NP) following COVID-19: prevalence and predictors	Alessandra Vergori, ROMA
15.56 - 16.01	322	OP 58 Is plasma neurofilament light chain measurement relevant in long-COVID?	Maria Antonella Zingaropoli, Roma
16.03 - 16.08	38	OP 59 SARS-CoV-2 hampers Dopamine production in iPS-derived dopaminergic neurons	Claudio Fenizia, Milano
16.10 - 16.15	325	OP 60 Early phase approach in SARS CoV-2 infection: a single center one-year real life experience	Daniela Di Trento, Latina
15/06/2022 15.35 - 16.25 New issues on dual therapy			
15.35 - 15.40	258	OP 61 Efficacy and Durability of Dual Antiretroviral Regimens as switch therapy in treatment-experienced People Living with HIV (PLWH): data from the ARCA cohort	Mariacristina Polisenò, Foggia
15.42 - 15.47	133	OP 62 Characterization of virologically suppressed HIV infected individuals potential eligible to the long-acting combination of cabotegravir plus rilpivirine: results from the Italian ARCA cohort	Adriana Cervo, Modena
15.49 - 15.54	324	OP 63 Long acting cabotegravir plus rilpivirine compassionate use program: a narrative description of the Italian experience	Roberto Rossotti, Milano
15.56 - 16.01	180	OP 64 Immunological recovery in PLWHIV starting dolutegravir plus lamivudine as first-line regimen: data from the ODOACRE cohort	Damiano Farinacci, L'Aquila
16.03 - 16.08	87	OP 65 Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine and Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors: a multicenter cohort study in Italy	Filippo Lagi, Firenze
16.10 - 16.15	195	OP 66 Comparing the efficacy and tolerability of dolutegravir plus rilpivirine versus dolutegravir plus lamivudine in a multicenter cohort	Damiano Farinacci, L'Aquila
15/06/2022 16.40 - 17.30 Cardiovascular diseases, osteoporosis but not only			
16.40 - 16.45	185	OP 67 Weight gain in people living with HIV under antiretroviral therapy: do our strategies make a difference?	Camilla Muccini, Milano
16.47 - 16.52	84	OP 68 PLWH (People Living With HIV): a single centre retrospective observational study on cardiovascular risk factors	Giuseppe Gasparro, Firenze
16.54 - 16.59	1	OP 69 Relationship between vitamin D deficiency and cardiovascular disease in virologically suppressed HIV-1-infected patients	Leonardo Calza, Bologna
17.01 - 17.06	26	OP 70 Effect of bisphosphonates on vertebral fractures in HIV infected males: a 7-years study	Samuele Storti, Brescia
17.08 - 17.13	202	OP 71 Association between Health Literacy, care engagement and assessment of risk behaviours in an Italian cohort of people living with HIV	Valentina Massaroni, Roma
17.15 - 17.20	125	OP 72 Mental health assessment in people living with HIV/AIDS (PLWHA): preliminary data from a referral HIV center	Flavia Balena, Bari



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



Elenco Oral Posters

Orario	ID	Title	Presenting Author
15/06/2022 16.40 - 17.30 Vulnerable and key populations: local experiences			
16.40 - 16.45	167	OP 73 Community-Based Centers (CBCs): sexual health needs and prevention knowledge among MSM in Lazio	Filippo Maria Nimbi, Roma
16.47 - 16.52	83	OP 74 Injecting drug use, irrespective of harm reduction measures, is strongly associated with HCV infection: results of a structured questionnaire administered during HCV screening sessions in low threshold harm reduction services	Alessandro Soria, Monza
16.54 - 16.59	27	OP 75 High prevalence of HCV infection among people screened in unconventional low threshold settings: results of an outreach program of screening and linkage to care for people using drugs	Alessandro Soria, Monza
17.01 - 17.06	124	OP 76 Descriptive analysis and retention in care of a cohort of HIV-positive migrants (AMIGO: A HIV-positive MIGrants cohort at AOU Careggi)	Filippo Lagi, Firenze
17.08 - 17.13	234	OP 77 A qualitative survey on facilitating factors and barriers to access and continuum of care: point of view of HIV-positive transgender migrant women living in Florence	Claudia Gatteschi, Firenze
15/06/2022 17.45 - 18.35 Measuring HIV stigma and disclosure			
17.45 - 17.50	16	OP 78 Tackling the misunderstanding and stigma of HIV: a survey on 1007 Italian citizens	Daniele Calzavara, Milano
17.52 - 17.57	46	OP 79 HIV-related stigma among Italian adults: results of an online survey	Vincenza Regine, Roma
17.59 - 18.04	209	OP 80 Determinants of non disclosure of HIV status in PLWHIV to other than health care workers	Antonella Cingolani, Roma
18.06 - 18.11	128	OP 81 Knowledge and impact of U=U among PLHIV, healthcare professionals and the general population in Italy: a qualitative study	Maria Luisa Cosmaro, Milano
18.13 - 18.18	235	OP 82 Do people living with HIV have a better knowledge of HIV and STIs compared to people without HIV? A survey study in Sardinia, Italy	Agnese Colpani, Sassari
18.20 - 18.25	69	OP 83 Impact of HIV-related stigma on social support, mental health and quality of life in an Italian cohort of people living with HIV	Valentina Delle Donne, Roma
15/06/2022 17.45 - 18.35 Models of COVID-19 pathogenesis and response to vaccination			
17.45 - 17.50	246	OP 84 Human iPSC-derived motor neurons are productively infected by SARS-CoV-2	Gioia Cappelletti, Milano
17.52 - 17.57	107	OP 85 SARS-CoV-2 infection of airway epithelium triggers endothelial cells activation	Davide Mariotti, Roma
17.59 - 18.04	276	OP 86 Specific CD4+ and CD8+ T cell response of SARS-CoV-2 S epitopes using tetramers & monocyte dysregulation in fully vaccinated donors and recovered patients	Alberico Parente, Roma
18.06 - 18.11	194	OP 87 Immune responses after three doses of BNT162b2 mRNA vaccine in a cohort of HIV-vertically transmitted patients	Claudia Vanetti, Milano
18.13 - 18.18	201	OP 88 Comparison between QuantiFERON SARS-CoV 2 kit and Activation Induced Cell Markers (AIMs) assay in 21 non-vaccinated patients with late COVID19 infection	Arianna Gatti, Legnano
18.20 - 18.25	267	OP 89 An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein	Maria Concetta Bellocchi, Roma



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**



www.icar2022.it



Elenco Oral Posters

Orario	ID	Title	Presenting Author
16/06/2022 10.05 - 10.55 COVID-19: considerations of special populations			
10.05 - 10.10	321	OP 90 Impact of patients' characteristics and comorbidities on in-hospital mortality during the first three waves of COVID-19 pandemic. Results from the Brescia HUB project	Irene Ettori, Brescia
10.12 - 10.17	8	OP 91 SARS-CoV-2 infection and COVID-19 disease in PLWH	Franco Maggiolo, Bergamo
10.19 - 10.24	314	OP 92 Evolution of SARS-CoV-2 Variants of Concerns (VOC) over a period of Delta and Omicron variants co-circulation: impact on clinical outcomes among patients (pts) hospitalized for COVID-19 in an Italian reference hospital in the first trimester of 2022	Annalisa Mondì, Roma
10.26 - 10.31	145	OP 93 New issues in SARS-CoV-2 vaccination response among Health-care workers: slow responders and peri-vaccination infections	Stefania Arsuffi, Brescia
10.33 - 10.38	232	OP 94 Antibody response in women vaccinated against SARS-CoV-2 during pregnancy and respective babies at birth	Stefano Agliardi, Milano
10.40 - 10.45	320	OP 95 Predictors of mortality in a cohort of oldest old subjects hospitalized for COVID-19	Maria Mazzitelli, Padova
16/06/2022 10.05 - 10.55 Toxicity of antiretroviral therapy			
10.05 - 10.10	2	OP 96 Efficacy and safety of switching to lamivudine/dolutegravir in HIV-1-infected patients aged over 65 years	Leonardo Calza, Bologna
10.12 - 10.17	61	OP 97 Specific neurodevelopmental consequences of dolutegravir exposure in a zebrafish embryo model and rescue with early folate treatment	Giorgio Tiecco, Brescia
10.19 - 10.24	251	OP 98 Causes of HIV treatment interruption during the last 20 years: a multi-cohort real-life study	Andrea De Vito, Sassari
10.26 - 10.31	169	OP 99 First and second phase viral load decay in real-life using Nonlinear Bayesian Mixed Effect model	Daniele Ceccarelli, Milano
10.33 - 10.38	173	OP 100 The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomized study	Barbara Rossetti, Grosseto
10.40 - 10.45	199	OP 101 Dynamic of lipid profile in HIV naive patients treated by TAF-based regimens: a multicenter observational study	Salvatore Martini, Napoli
16/06/2022 11.10 - 12.00 HIV and SARS-CoV-2: from in vivo to in vitro			
11.10 - 11.15	47	OP 102 Trends of HIV-1 drug resistance and APOBEC editing in PBMC compartment over the last decade	Daniele Armenia, Roma
11.17 - 11.22	172	OP 103 Trend over time of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and their drivers: cohort study from ARCA	Ilaria Rancan, Siena
11.24 - 11.29	220	OP 104 Sotrovimab-emergent resistance in immunocompromised COVID-19 patients	Federica Novazzi, Varese
11.31 - 11.36	196	OP 105 Tenofovir plasma and intracellular pharmacokinetics in INSTI-based regimens	Micol Ferrara, Torino
11.38 - 11.43	100	OP 106 Potent antiviral activity of new generation HIV-1 maturation inhibitors on human primary cells	Leonardo Duca, Roma
11.45 - 11.50	223	OP 107 Evaluation of the in vitro combinatorial activity of Ibalizumab and HIV-1 antivirals	Federica Giammarino, Siena



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



Elenco Oral Posters

Orario	ID	Title	Presenting Author
16/06/2022 12.15 - 13.05 Acute COVID-19 and post COVID-19 syndrome			
12.15 - 12.20	165 OP 108	Long-COVID syndrome data from 126,752 patients: a systematic review and meta-analysis	Alessandra Belati, Bari
12.22 - 12.27	66 OP 109	Post-Acute Sequelae of COVID-19 (PASC): An Italian Experience	Patrizia Pasculli, Roma
12.29 - 12.34	50 OP 110	A multidisciplinary model to screen and treat the post-COVID-19 Syndrome	Nicola Squillace, Monza
12.36 - 12.41	213 OP 111	Long term complications of COVID-19 in patients hospitalized in Clinica Malattie Infettive, Ospedali Riuniti, Ancona	Bianca Candelaresi, Ancona
12.43 - 12.48	181 OP 112	Outcome of patients with chronic liver disease hospitalized for SARS-CoV-2: a single centre matched cohort	Costanza Bertoni, Milano
12.50 - 12.55	269 OP 113	Characterization of three waves of covid 19 occurring in southern Italy: results of a multicentre cohort study	Viraj Pattapola, Caserta
16/06/2022 12.15 - 13.05 Immunological efficacy of COVID-19 vaccination in vulnerable populations			
12.15 - 12.20	343 OP 114	TNF-alfa expression is negatively correlated to seroconversion after SARS-CoV-2 mRNA BNT162b2 Vaccine in lung transplant patients	Mariasilvia Guardiani, Roma
12.22 - 12.27	345 OP 115	Different specific T cell responses to the third dose of mRNA COVID-19 vaccine in multiple sclerosis patients under disease-modifying treatments	Federica Dominelli, Roma
12.29 - 12.34	119 OP 116	SARS-CoV-2 vaccination effectiveness in Pemphigus Vulgaris Rituximab-treated patients	Claudio Fenizia, Milano
12.36 - 12.41	332 OP 117	SARS-CoV-2 antibody response in solid organ transplant patients after mRNA BNT162b2: data from an observational prospective study	Francesco Cogliati Dezza, Roma
12.43 - 12.48	236 OP 118	Durability of SARS-CoV-2 mRNA vaccine immune response in people living with HIV	Stefania Cicalini, Roma
12.50 - 12.55	152 OP 119	Decay pattern of Anti-SARS-CoV-2 Antibodies in PWH	Alessandro Tili, Modena
16/06/2022 13.15 - 14.05 Open questions about ART efficacy			
13.15 - 13.20	36 OP 120	Blood telomere length gain in virologically suppressed patients switching to dolutegravir plus lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study	Francesca Lombardi, Roma
13.22 - 13.27	127 OP 121	Real-life use of Doravirine in treatment-experienced people living with HIV: an Italian multicentre study	Melania Degli Antoni, Brescia
13.29 - 13.34	4 OP 122	Forgiveness to imperfect adherence to bicitegravir/emtricitabine/tenofovir alafenamide	Franco Maggiolo, Bergamo
13.36 - 13.41	54 OP 123	Evaluation of metabolic safety profile in naive and virologically suppressed HIV-1 infected individuals starting/switching to a bicitegravir single-tablet-regimen in a real-life setting	Marcello Trizzino, Palermo
13.43 - 13.48	293 OP 124	Real-world effectiveness of switching to bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in women living with HIV: subgroup analysis from ICONA-BIC	Alessandro Tavelli, Milano
13.50 - 13.55	313 OP 125	Tolerability, viro-immunological, metabolic effects, and costs of switching to BIC/TAF/FTC in a cohort of people living with HIV: a 48-week analysis	Maria Mazzitelli, Padova



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



Elenco Oral Posters

Orario	ID	Title	Presenting Author
16/06/2022 13.15 - 14.05 Immunological complexity in COVID-19			
13.15 - 13.20	82 OP 126	Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity	Alessandra Ruggiero, Verona
13.22 - 13.27	262 OP 127	Affinity maturation and neutralizing activity of anti-SARS-CoV-2 Spike antibodies	Sara Caucci, Ancona
13.29 - 13.34	95 OP 128	Correlation between clinical aspects and serum/CSF cytokine levels in early versus classic onset SARS-CoV-2-related Guillain-Barré Syndrome	Emanuele Pontali, Genova
13.36 - 13.41	253 OP 129	A real-life single-center study on the impact of anti-SARS-CoV2 vaccination	Cristiana Leanza, Roma
13.43 - 13.48	323 OP 130	Short course remdesivir in early Covid-19 as an effective and useful option in both out- and in-patients	Cosmo Del Borgo, Latina
13.50 - 13.55	182 OP 131	Dendritic cell maturation after infection with a clone of Leishmania tarentolae expressing the SARS-CoV-2 spike protein as a vaccine vehicle	Micaela Garziano, Milano
16/06/2022 14.20 - 15.10 Prevention and access to services during COVID pandemic			
14.20 - 14.25	28 OP 132	Narratives at the time of SARS-CoV-2 vaccination	Maria Giulia Marini, Milano
14.27 - 14.32	77 OP 133	Vaccine-preventable diseases in PLWH: adherence to recommendations in a single center in Northern Italy	Francesca Pennati, Brescia
14.34 - 14.39	144 OP 134	Impact of COVID-19 pandemic on sexual exposure and post-exposure prophylaxis (PEP) prescription appropriateness in a large Hospital, Northern Italy	Stefania Arsuffi, Brescia
14.41 - 14.46	143 OP 135	Looking for 90-90-90 goals: a real life experience during SARS-CoV-2 pandemia	Giorgia Brucci, Genova
14.48 - 14.53	164 OP 136	The impact of COVID-19 pandemic on access to HIV services at urban context-based health facilities supported by CUAMM in collaboration with UNICEF, in Beira Mozambique	Niccolò Ronzoni, Padova
14.55 - 15.00	311 OP 137	HAV, HBV and HPV vaccination coverage rate in a community-based pre-exposure prophylaxis program in Milan	Camilla Muccini, Milano
16/06/2022 14.20 - 15.10 SARS-CoV-2: from in vivo to in vitro			
14.20 - 14.25	204 OP 138	Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 waves	Rossana Scutari, Milano
14.27 - 14.32	211 OP 139	Rapid change in epidemiological and clinical characteristics of SARS-CoV-2 circulating variants in Italy in April-December 2021	Annalisa Bergna, Milano
14.34 - 14.39	228 OP 140	Higher viral load (VL) in nasopharyngeal swab (NPS) of individuals infected with Omicron BA.2 SARS-CoV-2, compared to Alpha, Gamma, Delta and Omicron BA.1 Variants Of Concern (VOCs)	Valentina Mazzotta, Roma
14.41 - 14.46	176 OP 141	Dopamine reduces SARS-CoV-2 replication through downregulation of D2 receptors and upregulation of Type-I Interferons	Fiona Limanaqi, Milano
14.48 - 14.53	62 OP 142	Developmental safety of nirmatrelvir in zebrafish embryos	Giorgio Tiecco, Brescia
14.55 - 15.00	40 OP 143	Peptidomimetic covalent reversible inhibitors exhibit broad-spectrum inhibition of CoVs Main protease and cellular activity against SARS-CoV-2: design, synthesis, biological evaluation, and structural biology	Rolando Cannarile, Napoli



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022

Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it 

Elenco Oral Posters

Orario	ID	Title	Presenting Author
16/06/2022	15.20 - 16.10	Immunopathogenesis of HIV	
15.20 - 15.25	121 OP 144	Distinctive features of immune markers of activation and exhaustion in adolescents and young adults people living with HIV infected perinatally vs. adult age	Chiara Dentone , Genova
15.27 - 15.32	272 OP 145	Lack of HIV Type 1 Antibody seroconversion in Acutely Infected Individuals Treated with Early Antiretroviral Therapy	Alessia Bertoldi, Bologna
15.34 - 15.39	154 OP 146	Evaluation of HCMV specific T-cell responses in PLWHIV and their correlation with the immune-virological status and clinical parameters	Marco Iannetta, Roma
15.41 - 15.46	210 OP 147	Crosstalk between gut microbiota and T cell responses in ART-treated HIV-1 infected patients	Letizia Santinelli, Roma
15.48 - 15.53	249 OP 148	Large proportion of new HIV diagnoses sustained by non-B subtypes – clinical and immunological correlates	Giorgio Bozzi, Milano